Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OxyContin Patent Settlement Limits Impax Market Share Even With ANDA Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

Generic manufacturer could begin selling either its own product or an authorized generic of the controlled-release opioid as early as Jan. 1, 2016.

You may also be interested in...

Purdue Looks To Patent Portfolio, FDA Guidance To Delay OxyContin Generics

Federal Circuit finds four OxyContin patents invalid, but authorized generics will continue to be only ones available for the near future.

Purdue NDA For Oxycodone/Naloxone Combo Tests New FDA Policy

The sponsor believes its data package could support a labeling claim that the drug “is expected to result in a meaningful reduction in abuse”; the agency’s review could indicate the strength of data needed to support such a claim.

Patent Expiration May Not Help OxyContin Generics

OxyContin’s method of treatment patent expires April 16, but several patents remain tied up in litigation over APIs as Purdue and generic companies await FDA decision on whether the original formulation can be a reference product.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts